Premium
Cost‐effectiveness of hepatitis A vaccination in children, adolescents, and adults
Author(s) -
Rosenthal Philip
Publication year - 2003
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1053/jhep.2003.50016
Subject(s) - medicine , vaccination , medline , public health , family medicine , pediatrics , hepatitis a , economic cost , environmental health , hepatitis a vaccine , hepatitis , immunology , political science , nursing , neoclassical economics , economics , law
Hepatitis A is a major public health problem in the United States and other developed countries, largely because decreased natural immunity allows for increased susceptibility. To evaluate the cost‐effectiveness of routine vaccination of children, adolescents, and certain high‐risk adults against hepatitis A, economic analyses of hepatitis A vaccination were identified through searches of MEDLINE, EMBASE, and BIOSIS (February, 1992, to December, 2001) for studies, reviews, editorials, and letters from peer‐reviewed journals published in English, French, German, Italian, or Spanish. Experts were also contacted. Articles conforming to accepted standards of quality for health‐economic studies were used to compile data on vaccination of children, and results were synthesized in a narrative review. This review of economic analyses of vaccine use in several developed countries shows cost‐effectiveness comparable with that of other vaccines in children and within accepted boundaries for adolescents and high‐risk adults.